Alpha Cognition Inc. (ACOG)
| Market Cap | 88.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.71M |
| Shares Out | 16.02M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,768 |
| Open | 5.51 |
| Previous Close | 5.31 |
| Day's Range | 5.26 - 5.63 |
| 52-Week Range | 4.66 - 7.00 |
| Beta | 2.51 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+261.66%) |
| Earnings Date | May 20, 2025 |
About ACOG
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc... [Read more]
Analyst Forecast
According to one analyst, the rating for ACOG stock is "Strong Buy" and the 12-month stock price forecast is $20.0.
News
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease
VANCOUVER--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerativ...
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition In...
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies fo...
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurode...
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call
DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerati...
Alpha Cognition Announces Partial Exercise of Over-allotment Option
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies fo...
CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)
Toronto, Ontario--(Newsfile Corp. - Le 16 décembre/December 2024) - The common shares of Alpha Cognition Inc. will be delisted from the CSE at market close December 17, 2024. Alpha Cognition will cont...
Alpha Cognition Announces Voluntary Delisting from CSE
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company's listing on the Nasdaq ...
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapi...
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debil...
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...